CJC-1295 vs Ipamorelin
CJC-1295 and Ipamorelin are two of the most frequently discussed growth hormone-releasing peptides. They act through different receptors but are often used together for a synergistic effect. Here is what the research says about each and how they compare.
Overview
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. The DAC (Drug Affinity Complex) version extends its half-life significantly, allowing for less frequent dosing. Ipamorelin is a growth hormone secretagogue that works via ghrelin receptors (GHS-R), triggering a sharp, pulse-like release of growth hormone with a high degree of selectivity and relatively few side effects.
How They Work
The key distinction is receptor pathway. CJC-1295 acts on GHRH receptors, amplifying the body's baseline growth hormone output over an extended period. Ipamorelin acts on ghrelin receptors and triggers discrete, pulsatile GH release that more closely mirrors the body's natural secretion pattern. Using both simultaneously targets two different receptor systems, which is why the combination is considered synergistic.
| Feature | CJC-1295 | Ipamorelin |
|---|---|---|
| Primary Use | Placeholder | Placeholder |
| Research Level | Placeholder | Placeholder |
| Administration | Placeholder | Placeholder |
Benefits Comparison
CJC-1295 Benefits
Placeholder — documented benefits including increased lean muscle mass, improved fat metabolism, enhanced recovery, and potential anti-aging effects will be detailed here with supporting research citations.
Ipamorelin Benefits
Placeholder — documented benefits including selective GH release, improved sleep quality, body composition improvements, and lower side-effect profile compared to older secretagogues will be detailed here with supporting research citations.
Side Effects
Both peptides are generally considered to have favorable safety profiles in the research literature when used appropriately. Common reported side effects across both compounds include transient water retention, mild flushing, and injection-site discomfort. CJC-1295 with DAC has been associated with a longer-lasting GH bleed, which may increase the chance of side effects. Ipamorelin's selectivity means it does not significantly raise cortisol or prolactin, which distinguishes it from earlier generation GH secretagogues.
Important Caveats
Placeholder — contraindications, long-term safety considerations, and population-specific notes will be added here. This page does not constitute medical advice.
The CJC/Ipa Stack
The CJC-1295 + Ipamorelin stack is one of the most commonly discussed GH peptide protocols in the research community. By combining a GHRH analog with a GHRP, users aim to saturate both stimulatory pathways simultaneously. The result is a more robust and sustained GH pulse than either peptide can produce alone.
Sample Protocol (Placeholder)
Specific dosing, injection timing, cycle length, and post-cycle considerations will be detailed here. Always work with a qualified healthcare provider before starting any peptide protocol.
Where to Buy
Sourcing from vendors who publish current, third-party Certificates of Analysis is essential for both safety and efficacy. We have reviewed and listed the best options below.
View Best Peptide Sources →Affiliate Disclosure: This page contains affiliate links. We only recommend vendors we have personally vetted for COA compliance. We may earn a commission at no extra cost to you.